NCT03335059View on ClinicalTrials.gov

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.

PHASE3TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions
Bladder CancerBladder NeoplasmBladder TumorsCancer of BladderCancer of the BladderMalignant Tumor of Urinary BladderNeoplasms, BladderUrinary Bladder CancerCarcinoma in Situ of BladderPapillary Carcinoma of Bladder (Diagnosis)BCG-Unresponsive Bladder Cancer
Interventions
COMBINATION_PRODUCT

Synergo® RITE + MMC

Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC

Trial Locations (4)

10029

Icahn School of Medicine at Mount Sinai, New York

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania, Philadelphia

21076

Chesapeake Urology Research Associates, Hanover

Sponsors
All Listed Sponsors
lead

Medical Enterprises Ltd.

INDUSTRY

NCT03335059 - Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. | Biotech Hunter | Biotech Hunter